1. Bruni L, Diaz M, Barrionuevo-Roses L, et al. Worldwide female and male HPV vaccination coverage from 2006 to 2016. International Papillomavirus Conference; Cape Town; Feb 28–March 4, 2017. View in Article Google Scholar

2. Cervical Cancer Action Global progress in HPV vaccination. http://www.cervicalcanceraction.org/comments/maps.php Date accessed: May 23, 2018 View in Article Google Scholar

4. Franco E

Schiffman M

Wacholder S

Stanley M Methodological issues for trials of vaccine efficacy against HPV types 16 and 18. in: ARC HPV Working Group Primary end-points for prophylactic vaccine trials. International Agency for Research on Cancer , Lyon : 39-45 View in Article Google Scholar

6. Liberati A

Altman DG

Tetzlaff J

et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339 b2700 View in Article Scopus (6292)

PubMed

Crossref

Google Scholar

7. Garland SM

Steben M

Sings HL

et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 199 : 805-814 View in Article Scopus (322)

PubMed

Crossref

Google Scholar

9. Deeks JJ

Higgins JPT

on behalf of the Statistical Methods Group of the Cochrane Collaboration Statistical algorithms in Review Manager 5. https://training.cochrane.org/handbook/statistical-methods-revman5 Date accessed: May 23, 2014 View in Article Google Scholar

10. Deeks JJ

Higgins PT

Altman DG Analysing data and undertaking meta-analyses. in: Higgins JPT Green S Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration , View in Article Google Scholar

11. Dillner J

Nygård M

Munk C

et al. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs. Vaccine. 36 : 3820-3829 View in Article Scopus (12)

PubMed

Crossref

Google Scholar

15. Dunne EF

Naleway A

Smith N

et al. Reduction in human papillomavirus vaccine type prevalence among young women screened for cervical cancer in an integrated US healthcare delivery system in 2007 and 2012–2013. J Infect Dis. 212 : 1970-1975 View in Article Scopus (19)

PubMed

Crossref

Google Scholar

16. Grün N

Ährlund-Richter A

Franzén J

et al. Follow-up on oral and cervical human papillomavirus prevalence 2013–2015 in youth at a youth clinic in Stockholm, Sweden. Infect Dis (Lond). 48 : 169-170 View in Article Scopus (4)

PubMed

Crossref

Google Scholar

17. Kavanagh K

Pollock KG

Potts A

et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 110 : 2804-2811 View in Article Scopus (121)

PubMed

Crossref

Google Scholar

18. Cameron RL

Kavanagh K

Pan J

et al. Human papillomavirus prevalence and herd immunity after introduction of vaccination program, Scotland, 2009–2013. Emerg Infect Dis. 22 : 56-64 View in Article Scopus (70)

PubMed

Crossref

Google Scholar

21. Kahn JA

Widdice LE

Ding L

et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis. 63 : 1281-1287 View in Article Scopus (27)

PubMed

Crossref

Google Scholar

22. Machalek DA

Garland SM

Brotherton JML

et al. Very low prevalence of vaccine human papillomavirus types among 18- to 35-year old Australian women 9 years following implementation of vaccination. J Infect Dis. 217 : 1590-1600 View in Article Scopus (51)

PubMed

Crossref

Google Scholar

23. Markowitz LE

Hariri S

Lin C

et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 208 : 385-393 View in Article Scopus (360)

PubMed

Crossref

Google Scholar

24. Markowitz LE

Liu G

Hariri S

Steinau M

Dunne EF

Unger ER Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 137 e20151968 View in Article Scopus (179)

PubMed

Crossref

Google Scholar

25. Oliver SE

Unger ER

Lewis R

et al. Prevalence of human papillomavirus among females after vaccine introduction—National Health and Nutrition Examination Survey, United States, 2003–2014. J Infect Dis. 216 : 594-603 View in Article Scopus (53)

PubMed

Crossref

Google Scholar

26. Mesher D

Panwar K

Thomas SL

Beddows S

Soldan K Continuing reductions in HPV 16/18 in a population with high coverage of bivalent HPV vaccination in England: an ongoing cross-sectional study. BMJ Open. 6 e009915 View in Article Scopus (36)

PubMed

Crossref

Google Scholar

27. Mesher D

Soldan K

Howell-Jones R

et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 32 : 26-32 View in Article Scopus (86)

PubMed

Crossref

Google Scholar

28. Mesher D

Panwar K

Thomas SL

et al. The impact of the national HPV vaccination program in England using the bivalent HPV vaccine: surveillance of type-specific HPV in young females, 2010–2016. J Infect Dis. 218 : 911-921 View in Article Scopus (28)

PubMed

Crossref

Google Scholar

29. Purriños-Hermida MJ

Santiago-Pérez MI

Treviño M

et al. Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain. PLoS One. 13 e0201653 View in Article Scopus (4)

PubMed

Crossref

Google Scholar

30. Söderlund-Strand A

Uhnoo I

Dillner J Change in population prevalences of human papillomavirus after initiation of vaccination: the high-throughput HPV monitoring study. Cancer Epidemiol Biomarkers Prev. 23 : 2757-2764 View in Article Scopus (40)

PubMed

Crossref

Google Scholar

32. Tabrizi SN

Brotherton JML

Kaldor JM

et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 206 : 1645-1651 View in Article Scopus (190)

PubMed

Crossref

Google Scholar

34. Ali H

Donovan B

Wand H

et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 346 f2032 View in Article Scopus (291)

PubMed

Crossref

Google Scholar

35. Ali H

McManus H

O'Connor CC

et al. Human papillomavirus vaccination and genital warts in young Indigenous Australians: national sentinel surveillance data. Med J Aust. 206 : 204-209 View in Article Scopus (16)

PubMed

Crossref

Google Scholar

36. Chow EP

Read TR

Wigan R

et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 91 : 214-219 View in Article Scopus (61)

PubMed

Crossref

Google Scholar

37. Callander D

Ali H

Donovan B Genital Warts Surveillance Network report 2004-2015. The Kirby Institute , Sydney, NSW View in Article Google Scholar

38. Baandrup L

Blomberg M

Dehlendorff C

Sand C

Andersen KK

Kjaer SK Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 40 : 130-135 View in Article Scopus (108)

PubMed

Crossref

Google Scholar

39. Bollerup S

Baldur-Felskov B

Blomberg M

Baandrup L

Dehlendorff C

Kjaer SK Significant reduction in the incidence of genital warts in young men 5 years into the Danish human papillomavirus vaccination program for girls and women. Sex Transm Dis. 43 : 238-242 View in Article Scopus (26)

PubMed

Crossref

Google Scholar

40. Bauer HM

Wright G

Chow J Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health. 102 : 833-835 View in Article Scopus (84)

PubMed

Crossref

Google Scholar

41. Cocchio S

Baldovin T

Bertoncello C

et al. Decline in hospitalization for genital warts in the Veneto region after an HPV vaccination program: an observational study. BMC Infect Dis. 17 : 249 View in Article Scopus (9)

PubMed

Crossref

Google Scholar

42. Dominiak-Felden G

Gobbo C

Simondon F Evaluating the early benefit of quadrivalent HPV vaccine on genital warts in Belgium: a cohort study. PLoS One. 10 e0132404 View in Article Scopus (24)

PubMed

Crossref

Google Scholar

43. Flagg EW

Schwartz R

Weinstock H Prevalence of anogenital warts among participants in private health plans in the United States, 2003–2010: potential impact of human papillomavirus vaccination. Am J Public Health. 103 : 1428-1435 View in Article Scopus (64)

PubMed

Crossref

Google Scholar

44. Flagg EW

Torrone EA Declines in anogenital warts among age groups most likely to be impacted by human papillomavirus vaccination, United States, 2006–2014. Am J Public Health. 108 : 112-119 View in Article Scopus (19)

PubMed

Crossref

Google Scholar

45. Guerra FM

Rosella LC

Dunn S

Wilson SE

Chen C

Deeks SL Early impact of Ontario's human papillomavirus (HPV) vaccination program on anogenital warts (AGWs): a population-based assessment. Vaccine. 34 : 4678-4683 View in Article Scopus (13)

PubMed

Crossref

Google Scholar

46. Harrison C

Britt H

Garland S

et al. Decreased management of genital warts in young women in Australian general practice post introduction of national HPV vaccination program: results from a nationally representative cross-sectional general practice study. PLoS One. 9 e105967 View in Article Scopus (27)

PubMed

Crossref

Google Scholar

47. Howell-Jones R

Soldan K

Wetten S

et al. Declining genital warts in young women in England associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 208 : 1397-1403 View in Article Scopus (52)

PubMed

Crossref

Google Scholar

48. Canvin M

Sinka K

Hughes G

Mesher D Decline in genital warts diagnoses among young women and young men since the introduction of the bivalent HPV (16/18) vaccination programme in England: an ecological analysis. Sex Transm Infect. 93 : 125-128 View in Article Scopus (33)

PubMed

Crossref

Google Scholar

49. Kliewer EV, Mahmud SM, Demers AA, Lambert P, Musto G. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba, Canada. 28th International Papillomavirus Conference; San Juan, Puerto Rico; Nov 30–Dec 6, 2012. Abstract E07–663. View in Article Google Scholar

50. Thompson LH

Nugent Z

Blanchard JF

Ens C

Yu BN Increasing incidence of anogenital warts with an urban-rural divide among males in Manitoba, Canada, 1990–2011. BMC Public Health. 16 : 219 View in Article Scopus (3)

PubMed

Crossref

Google Scholar

51. Leval A

Herweijer E

Arnheim-Dahlström L

et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis. 206 : 860-866 View in Article Scopus (80)

PubMed

Crossref

Google Scholar

52. Herweijer E

Ploner A

Sparén P Substantially reduced incidence of genital warts in women and men six years after HPV vaccine availability in Sweden. Vaccine. 36 : 1917-1920 View in Article Scopus (8)

PubMed

Crossref

Google Scholar

53. Liu B

Donovan B

Brotherton JM

Saville M

Kaldor JM Genital warts and chlamydia in Australian women: comparison of national population-based surveys in 2001 and 2011. Sex Transm Infect. 90 : 532-537 View in Article Scopus (6)

PubMed

Crossref

Google Scholar

54. Mikolajczyk RT

Kraut AA

Horn J

Schulze-Rath R

Garbe E Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany —An ecologic study. Sex Transm Dis. 40 : 28-31 View in Article Scopus (29)

PubMed

Crossref

Google Scholar

55. Thöne K

Horn J

Mikolajczyk R Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC Infect Dis. 17 : 564 View in Article Scopus (7)

PubMed

Crossref

Google Scholar

56. Oliphant J

Perkins N Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services. N Z Med J. 124 : 51-58 View in Article PubMed

Google Scholar

57. Oliphant J

Stewart J

Saxton P

Lo M

Perkins N

Ward D Trends in genital warts diagnoses in New Zealand five years following the quadrivalent human papillomavirus vaccine introduction. N Z Med J. 130 : 9-16 View in Article PubMed

Google Scholar

58. Smith MA

Liu B

McIntyre P

Menzies R

Dey A

Canfell K Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis. 211 : 91-99 View in Article Scopus (48)

PubMed

Crossref

Google Scholar

59. Smith MA

Liu B

McIntyre P

Menzies R

Dey A

Canfell K Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data. BMC Infect Dis. 16 : 52 View in Article Scopus (12)

PubMed

Crossref

Google Scholar

60. Sonnenberg P, Tanton C, King E, et al. Genital warts & HPV 6/11 in the British population: data from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). 31st International Papillomavirus Conference; Cape Town; Feb 28–March 4, 2017. Abstract 454. View in Article Google Scholar

61. Steben M

Ouhoummane N

Rodier C

Sinyavskaya L

Brassard P The early impact of human papillomavirus vaccination on anogenital warts in Québec, Canada. J Med Virol. 90 : 592-598 View in Article Scopus (9)

PubMed

Crossref

Google Scholar

63. Sandø N

Kofoed K

Zachariae C

Fouchard J A reduced national incidence of anogenital warts in young Danish men and women after introduction of a national quadrivalent human papillomavirus vaccination programme for young women – an ecological study. Acta Derm Venereol. 94 : 288-292 View in Article Scopus (19)

PubMed

Crossref

Google Scholar

64. Nsouli-Maktabi H

Ludwig SL

Yerubandi UD

Gaydos JC Incidence of genital warts among U.S. service members before and after the introduction of the quadrivalent human papillomavirus vaccine. MSMR. 20 : 17-20 View in Article PubMed

Google Scholar

65. Baldur-Felskov B

Dehlendorff C

Junge J

Munk C

Kjaer SK Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 25 : 915-922 View in Article Scopus (51)

PubMed

Crossref

Google Scholar

66. Baldur-Felskov B

Munk C

Nielsen TSS

et al. Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997–2012. Cancer Causes Control. 26 : 1105-1116 View in Article Scopus (35)

PubMed

Crossref

Google Scholar

67. Benard VB

Castle PE

Jenison SA

et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 3 : 833-837 View in Article Scopus (47)

PubMed

Crossref

Google Scholar

69. Australian Institute of Health and Welfare Cervical screening in Australia 2013–2014. National Cervical Screening Program. https://www.aihw.gov.au/getmedia/c5e7776b-907e-4467-b435-8d6863ef33e7/19750.pdf.aspx?inline=true Date accessed: November 2, 2018 View in Article Google Scholar

70. Australian Institute of Health and Welfare Cervical screening in Australia: 2018. National Cervical Screening Program. https://www.aihw.gov.au/getmedia/8a26b34d-a912-4f01-b646-dc5d0ca54f03/aihw-can-111.pdf.aspx?inline=true Date accessed: January 25, 2019 View in Article Google Scholar

71. Flagg EW

Torrone EA

Weinstock H Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007–2014. Am J Public Health. 106 : 2211-2218 View in Article Scopus (27)

PubMed

Crossref

Google Scholar

72. Gargano JW

Park IU

Griffin MR

et al. Trends in high-grade cervical lesions and cervical cancer screening in five states, 2008–2015. Clin Infect Dis. ( ) DOI:10.1093/cid/ciy707 View in Article PubMed

Google Scholar

73. Niccolai LM

Julian PJ

Meek JI

McBride V

Hadler JL

Sosa LE Declining rates of high-grade cervical lesions in young women in Connecticut, 2008–2011. Cancer Epidemiol Biomarkers Prev. 22 : 1446-1450 View in Article Scopus (46)

PubMed

Crossref

Google Scholar

74. Niccolai LM

Meek JI

Brackney M

Hadler JL

Sosa LE

Weinberger DM Declines in human papillomavirus (HPV)–associated high-grade cervical lesions after introduction of HPV vaccines in Connecticut, United States, 2008–2015. Clin Infect Dis. 65 : 884-889 View in Article Scopus (13)

PubMed

Crossref

Google Scholar

75. Liaw KL

Kjaer S

Nygard M

Dillner J Utilization of nordic countries national registries to monitor the impact of HPV vaccination. Pharmacoepidemiol Drug Saf. 23 : 356 View in Article Google Scholar

76. Ogilvie GS

Naus M

Money DM

et al. Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: an ecological analysis. Int J Cancer. 137 : 1931-1937 View in Article Scopus (25)

PubMed

Crossref

Google Scholar

77. Pollock KG

Kavanagh K

Potts A

et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 111 : 1824-1830 View in Article Scopus (106)

PubMed

Crossref

Google Scholar

78. Chen HY

Kessler CL

Mori N

Chauhan SP Cervical cancer screening in the United States, 1993–2010: characteristics of women who are never screened. J Womens Health (Larchmt). 21 : 1132-1138 View in Article Scopus (31)

PubMed

Crossref

Google Scholar

79. Jemal A

Simard EP

Dorell C

et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 105 : 175-201 View in Article Scopus (694)

PubMed

Crossref

Google Scholar

80. Tiro JA

Tsui J

Bauer HM

Yamada E

Kobrin S

Breen N Human papillomavirus vaccine use among adolescent girls and young adult women: an analysis of the 2007 California Health Interview Survey. J Womens Health (Larchmt). 21 : 656-665 View in Article Scopus (38)

PubMed

Crossref

Google Scholar

82. Drolet M

Laprise JF

Brotherton JML

et al. The impact of human papillomavirus catch-up vaccination in Australia: implications for introduction of multiple age cohort vaccination and postvaccination data interpretation. J Infect Dis. 216 : 1205-1209 View in Article Scopus (18)

PubMed

Crossref

Google Scholar

83. Chaiyakunapruk N, Ng SS. Summary of evidence. Human papillomavirus (HPV) vaccination: an updated systematic review of cost-effectiveness analyses. Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE); Geneva; October, 2016. View in Article Google Scholar

84. WHO Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec. 89 : 465-491 View in Article PubMed

Google Scholar

85. Meites E

Kempe A

Markowitz LE Use of a 2-dose schedule for human papillomavirus vaccination —updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 65 : 1405-1408 View in Article Scopus (331)

PubMed

Crossref

Google Scholar

87. National Advisory Committee on Immunization (NACI) Statement on human papillomavirus vaccine. An advisory committee statement (ACS). Can Commun Dis Rep. 33 : 1-31 View in Article Google Scholar

88. US Food and Drug Administration Vaccines, blood & biologics: Gardasil. https://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094042.htm Date accessed: May 2, 2019 View in Article Google Scholar

89. European Centre for Disease Prevention and Control Guidance for the introduction of HPV vaccines in EU countries. Stockholm. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0801_GUI_Introduction_of_HPV_Vaccines_in_EU.pdf Date: January, 2008 Date accessed: May 2, 2019 View in Article Google Scholar

91. Canfell K

Caruana M

Gebski V

et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the compass pilot randomised trial. PLoS Med. 14 e1002388 View in Article Scopus (37)

PubMed

Crossref

Google Scholar

92. Drolet M

Boily MC

Greenaway C

et al. Sociodemographic inequalities in sexual activity and cervical cancer screening: implications for the success of human papillomavirus vaccination. Cancer Epidemiol Biomarkers Prev. 22 : 641-652 View in Article Scopus (24)

PubMed

Crossref

Google Scholar

93. Herweijer E

Feldman AL

Ploner A

et al. The participation of HPV-vaccinated women in a national cervical screening program: population-based cohort study. PLoS One. 10 e0134185 View in Article Scopus (21)

PubMed

Crossref

Google Scholar

94. Tanton C

Soldan K

Beddows S

et al. High-risk human papillomavirus (HPV) infection and cervical cancer prevention in Britain: Evidence of differential uptake of interventions from a probability survey. Cancer Epidemiol Biomarkers Prev. 24 : 842-853 View in Article Scopus (18)

PubMed

Crossref

Google Scholar

95. Brotherton JML

Gertig DM

May C

Chappell G

Saville M HPV vaccine impact in Australian women: ready for an HPV-based screening program. Med J Aust. 204 : 184 View in Article Scopus (38)

PubMed

Crossref

Google Scholar

96. Liu G

Hariri S

Bradley H

Gottlieb SL

Leichliter JS

Markowitz LE Trends and patterns of sexual behaviors among adolescents and adults aged 14 to 59 years, United States. Sex Transm Dis. 42 : 20-26 View in Article Scopus (65)

PubMed

Crossref

Google Scholar

99. Rissel C

Badcock PB

Smith AM

et al. Heterosexual experience and recent heterosexual encounters among Australian adults: the Second Australian Study of Health and Relationships. Sex Health. 11 : 416-426 View in Article Scopus (41)

PubMed

Crossref

Google Scholar

100. Jensen KE

Munk C

Sparen P

et al. Women's sexual behavior. Population-based study among 65,000 women from four Nordic countries before introduction of human papillomavirus vaccination. Acta Obstet Gynecol Scand. 90 : 459-467 View in Article Scopus (29)

PubMed

Crossref

Google Scholar

101. Stenhammar C

Ehrsson YT

Åkerud H

Larsson M

Tydén T Sexual and contraceptive behavior among female university students in Sweden—repeated surveys over a 25-year period. Acta Obstet Gynecol Scand. 94 : 253-259 View in Article Scopus (28)

PubMed

Crossref

Google Scholar

102. Herlitz CA

Forsberg M Sexual behaviour and risk assessment in different age cohorts in the general population of Sweden (1989–2007). Scand J Public Health. 38 : 32-39 View in Article Scopus (30)

PubMed

Crossref

Google Scholar

103. Cocchio S

Bertoncello C

Baldovin T

Buja A

Majori S

Baldo V Self-reported genital warts among sexually-active university students: a cross-sectional study. BMC Infect Dis. 18 : 41 View in Article Scopus (6)

PubMed

Crossref

Google Scholar

105. Mori S

Nakao S

Kukimoto I

Kusumoto-Matsuo R

Kondo K

Kanda T Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci. 102 : 1223-1227 View in Article Scopus (32)

PubMed

Crossref

Google Scholar